Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved therapies for these tumors and their relentless progression results in high rates of morbidity an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Long-Sheng, Oblinger, Janet L., Smith, Abbi E., Ferrer, Marc, Angus, Steven P., Hawley, Eric, Petrilli, Alejandra M., Beauchamp, Roberta L., Riecken, Lars Björn, Erdin, Serkan, Poi, Ming, Huang, Jie, Bessler, Waylan K., Zhang, Xiaohu, Guha, Rajarshi, Thomas, Craig, Burns, Sarah S., Gilbert, Thomas S. K., Jiang, Li, Li, Xiaohong, Lu, Qingbo, Yuan, Jin, He, Yongzheng, Dixon, Shelley A. H., Masters, Andrea, Jones, David R., Yates, Charles W., Haggarty, Stephen J., La Rosa, Salvatore, Welling, D. Bradley, Stemmer-Rachamimov, Anat O., Plotkin, Scott R., Gusella, James F., Guinney, Justin, Morrison, Helen, Ramesh, Vijaya, Fernandez-Valle, Cristina, Johnson, Gary L., Blakeley, Jaishri O., Clapp, D. Wade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282008/
https://www.ncbi.nlm.nih.gov/pubmed/34264955
http://dx.doi.org/10.1371/journal.pone.0252048

Ejemplares similares

Ejemplares similares